ALXO Open Interest
ALX Oncology Holdings Inc (ALXO) had 5.32K open option contracts as of Nov 4, 2026: 5.09K calls and 225 puts. Open interest rose 131.8% over the past four weeks, and is ALXO's highest level in 12 weeks. The put/call open interest ratio is 0.04, so calls outnumber puts.
Open Interest by Strike
Showing results for ALXO, 2026-11-20(m), calls & puts
Open Interest Stats
Showing results for ALXO, 2026-11-20(m), calls & puts
| Call Open Interest Total | |
|---|---|
| Put Open Interest Total | |
| Open Interest Total | |
| Put-Call Open Interest Ratio |
Highest Open Interest Options
Showing results for ALXO, 2026-11-20(m), calls & puts
Open Interest Total by Expiry
Showing results for ALXO, 2026-11-20(m), calls & puts. View all expiries
Open Interest History
Showing daily totals for ALXO, all expirations, calls & puts. View full history
ALXO Open Interest FAQ
What is open interest?
Open interest is the number of option contracts that are open and not yet closed, exercised, or expired. The Options Clearing Corporation calculates it once a day from the previous day's trades, and it is published before the market opens.
How much open interest does ALXO have?
ALX Oncology had 5.32K open option contracts as of Nov 4, 2026. Over the past 30 days, open interest averaged 3.74K contracts.
Is ALXO open interest rising or falling?
Open interest rose 131.8% over the past four weeks, and is ALXO's highest level in 12 weeks. It was 2.29K contracts on Oct 7, 2026. See the ALXO open interest history for a longer view.
What is the ALXO put/call open interest ratio?
The ALX Oncology put/call open interest ratio was 0.04 as of Nov 4, 2026. Four weeks earlier it was 0.07.
What is ALX Oncology Holdings Inc?
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials.